[{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Extracellular calcium-sensing receptor; Calreticulin; Calcium and integrin-binding protein 1; Programmed cell death protein 6; Sorcin; Calcineurin B homologous protein 1; SPARC; Calnexin; Fibrillin-2; Protein S100-B; Calsequestrin-2; Regucalcin; Peflin; Protein S100-A6; Translationally-controlled tumor protein; Calcium and integrin-binding family member 2; Protein S100-A13; Calsequestrin-1; Nucleobindin-1; Nucleobindin-2; Fibrillin-3; Grancalcin; Calcium-dependent secretion activator 1; Calmodulin-2; Calmodulin-3; Protein S100-A16; Calretinin; Calcyphosin; Calcium-dependent secretion activator 2; Calreticulin-3; Neurexin-1; Neuronal calcium sensor 1; Calmodulin","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"||Extracellular calcium-sensing receptor; Calreticulin; Calcium and integrin-binding protein 1; Programmed cell death protein 6; Sorcin; Calcineurin B homologous protein 1; SPARC; Calnexin; Fibrillin-2; Protein S100-B; Calsequestrin-2; Regucalcin; Peflin; Protein S100-A6; Translationally-controlled tumor protein; Calcium and integrin-binding family member 2; Protein S100-A13; Calsequestrin-1; Nucleobindin-1; Nucleobindin-2; Fibrillin-3; Grancalcin; Calcium-dependent secretion activator 1; Calmodulin-2; Calmodulin-3; Protein S100-A16; Calretinin; Calcyphosin; Calcium-dependent secretion activator 2; Calreticulin-3; Neurexin-1; Neuronal calcium sensor 1; Calmodulin","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR442501","moa":"Fibroblast growth factor receptor 3 (FGFR3)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR442501","moa":"Fibroblast growth factor receptor 3 (FGFR3)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xalud Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Causeway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tenomir","moa":"miRNA","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Causeway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Causeway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Causeway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Causeway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tenomir","moa":"miRNA","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Causeway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Causeway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Causeway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Tennessee Graduate School of Medicine","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University of Tennessee Graduate School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tennessee Graduate School of Medicine \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"University of Tennessee Graduate School of Medicine \/ Attralus"},{"orgOrder":0,"company":"IWK Health Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"IWK Health Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IWK Health Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IWK Health Centre \/ Undisclosed"},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"Avania | Kuros Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TGplPTH1-34","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kuros Biosciences \/ Avania | Kuros Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ Avania | Kuros Biosciences"},{"orgOrder":0,"company":"Indiana Hand to Shoulder Center","sponsor":"CTM Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefotiam","moa":"Peptidoglycan synthase FtsI; Penicillin-binding protein 1A","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Indiana Hand to Shoulder Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana Hand to Shoulder Center \/ CTM Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Indiana Hand to Shoulder Center \/ CTM Biomedical"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Gencor","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Gencor","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Irvine \/ Gencor"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allob","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Icon Plc"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Pregene"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Bone Therapeutics"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"ScinnoHub Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BT-14143","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"ScinnoHub Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KN060","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Beta-tricalcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp"}]

Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : SAR442501

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Study Phase : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : SAR442501 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteochondrodysplasias.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 04, 2023

                          Lead Product(s) : SAR442501

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          ScinnoHub Pharmaceutical Co., Ltd.

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          ScinnoHub Pharmaceutical Co., Ltd.

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : BT-14143 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthroplasty, Replacement, Knee.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 17, 2025

                          Lead Product(s) : BT-14143

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Tennessee Graduate School of Medicine

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          University of Tennessee Graduate School of Medicine

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : 124-I Evuzamitide is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lumbar Spinal Stenosis.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : 124-I Evuzamitide

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Attralus

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 13, 2024

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 16, 2024

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IWK Health Centre

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          IWK Health Centre

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Aprepitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Spinal Fusion.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 10, 2024

                          Lead Product(s) : Aprepitant

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Causeway Therapeutics

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Causeway Therapeutics

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : TenoMiR (Tenomir) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tennis Elbow.

                          Product Name : TenoMiR

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 05, 2024

                          Lead Product(s) : Tenomir

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : KN060 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthroplasty, Replacement, Knee.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 26, 2023

                          Lead Product(s) : KN060

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 18, 2023

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Maruishi Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank